 |
|
|
| |
Mechanistic pharmacokinetics/pharmacodynamics modelling of the simultaneous effects of bepirovirsen on hepatitis B surface antigen and alanine transaminase changes in chronic hepatitis B patients:
Phase 2b analysis to inform Phase 3 decision-making
|
| |
| |
EASL 2022 June 22-26 London
Youssef AS1, Ismail M2, Magee M1, Theodore D3, Paff M4, Elston R5, Nader A1
1Clinical Pharmacology Modeling and Simulation, GlaxoSmithKline, Collegeville, PA, USA; 2Enhanced Pharmacodynamics LLC, Buffalo, NY, USA; 3Development Clinical Sciences Hepatology/GI, GlaxoSmithKline, Research Triangle, NC, USA; 4Development, GlaxoSmithKline, Collegeville, PA, USA 5Development, Clinical Sciences Hepatology/GI, GlaxoSmithKline, Stevenage, Hertfordshire, UK
|
| |
|
|
|
|
|
